DeepMind's structure prediction tool has been used in 2 million research projects.
Editorial desk for The Spec'd — technology coverage at full resolution. Published by Hyphn Media Inc., Toronto.
Semaglutide's primary patents expire between 2026 and 2031, opening the market to biosimilars.
Semaglutide and tirzepatide are showing strong efficacy against alcohol, nicotine, and opioid addiction in early trials.
After COVID mRNA vaccines, Moderna and Pfizer have completed Phase 3 trials for influenza with substantially better efficacy.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Leave a Reply